Tag: HIV
-
FDA Approves Pediatric HIV Drug Formulation
5 June 2015. The U.S. Food and Drug Administration approved an application for a current HIV drug formulated to better treat infections in infants and young children, especially in limited resource regions. The formulation is a combination of lopinavir and ritonavir in pellet form designed to mix with food, and manufactured by the generic drug…
-
GSK, UNC Chapel Hill Partner on HIV/AIDS Cure
11 May 2015. Pharmaceutical maker GlaxoSmithKline and University of North Carolina in Chapel Hill are establishing a joint research center and spin-off company to develop new treatments for HIV and AIDS. GSK says it plans to invest $20 million over 5 years for a new HIV Cure Center on the Chapel Hill campus to conduct…
-
Biotech, Universities to Test Hydrogel for Vocal Fold Scars
28 August 2014. BioTime Inc., a biotechnology company in Alameida, California, is partnering with researchers at University of Wisconsin and Université catholique de Louvain in Belgium to test its hydrogels for treating vocal cord scarring, a voice problem that results from injury or disease. Financial terms of the collaboration were not disclosed. Vocal folds are…
-
Early Trial Shows Gene Editing Potential to Treat HIV/AIDS
6 March 2014. Researchers from University of Pennsylvania, Albert Einstein College of Medicine, and the biotechnology company Sangamo BioSciences showed the company’s gene-editing technology could engineer the immune cells of HIV-positive patients to resist infection and decrease their viral loads. Results of the early-stage clinical trial led by Penn immunologist Carl June will be presented…
-
Lab-On-Chip Diagnostics Company Lands $2.1M Angel Financing
ChipCare Corp., a spin-off company from University of Toronto in Canada developing hand-held diagnostics devices to replace fixed expensive lab equipment, secured $2.05 million in early stage angel financing. The deal combines investments from university, private-sector, and Canadian government sources, according to an announcement by Grand Challenges Canada, a government-financed organization supporting medical innovations in…
-
Community Pharmacies Found Helpful in Encouraging HIV Tests
Medical researchers at Albert Einstein College of Medicine of Yeshiva University in New York found local pharmacies can serve as venues to offer rapid HIV screening and get medical care for those who test positive. The team from Einstein College and its affiliated Jacobi Medical Center in the Bronx published its findings in this month’s…
-
Algorithm Identifies HIV Antibodies For Vaccine Design
Biologists at National Institute of Allergy and Infectious Diseases (NIAID), part of National Institutes of Health, developed a mathematical model to highlight antibodies that neutralize viruses in people with HIV, which can help design a vaccine against HIV infection. The team from NIAID’s Vaccine Research Center, with colleagues from Columbia University and research institutes in…
-
NIH Stops HIV Vaccine Immunizations in Clinical Trial
National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will stop testing an HIV vaccine candidate, after interim results showed the vaccine stopped neither HIV infections nor the amount of HIV in the blood. The HVTN 505 study, a phase 2 clinical trial of safety and efficacy begun in…
-
Mylan Acquires Generic Injectables Manufacturer for $1.6B
Mylan Inc., a producer of generic and specialty branded drugs in Pittsburgh, will acquire Agila Specialties in Bangalore, India, a developer of generic inectable drugs and division of Strides Arcolab Ltd. Mylan will pay $1.6 billion cash for Agila Specialties, with up to $250 million in contingent payments possible later on. Mylan offers some 1,100…
-
Generic HIV Drugs Save Money, But Could Impair Effectiveness
Researchers at Weill Cornell Medical College in New York, Massachusetts General Hospital in Boston, and Yale University in New Haven calculate that switching generic for branded HIV drugs would provide substantial financial savings, but could impede the treatments’ effectiveness. The team’s findings appear in today in the journal Annals of Internal Medicine (paid subscription required).…